España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Provectus
PVCT
OTCQB
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$0.119900
0.0062
5.45%
At close: -
Get Report
Comment
Provectus (PVCT) Forecast
News
Earnings
Provectus (PVCT) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Provectus (OTC:PVCT) Stock
Provectus Stock (OTC: PVCT)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, May 21, 2024
Provectus Biopharmaceuticals Presents Rose Be...
Benzinga Newsdesk
Tuesday, January 24, 2023
Short Volatility Alert: Provectus Biopharm
Christopher Sappo
Tuesday, January 17, 2023
Trading Volume In The OTCQB Venture Market Picks Up in December – A Summary Of OTC Market Group's Most Active List In December
Jad Malaeb
-
Sponsored
Wednesday, April 27, 2022
Several Companies Highlight Upcoming Presenta...
Benzinga Newsdesk
Tuesday, March 24, 2020
Stocks That Hit 52-Week Highs On Tuesday
Benzinga Insights
Wednesday, August 24, 2016
Provectus Biopharmaceuticals Proposes "Best E...
Benzinga
Provectus Biopharmaceuticals, Inc. Announces ...
Benzinga
Tuesday, August 23, 2016
Provectus Biopharma Announces Patent For Rose...
Benzinga
Monday, July 18, 2016
Provectus Biopharma Gets Patent For Halogenat...
Benzinga
Thursday, July 14, 2016
Provectus Biopharma Announces Austrailian Subsidiary Formed
Benzinga
Wednesday, July 13, 2016
Provectus Biopharmaceuticals Announces PV-10 Data Discussed at 6th European Post-Chicago Melanoma/Skin Cancer Meeting
Benzinga
Tuesday, July 12, 2016
Provectus Biopharmaceuticals Announces Acceptance of Abstract for Poster Presentation at ESMO 2016 Congress
Benzinga
Monday, June 13, 2016
Provectus Biopharmaceuticals Enters Stipulation Of Settlement In Shareholder Derivative Action
Benzinga
Tuesday, June 07, 2016
Provectus Biopharmaceuticals Announces Publication of Article on PV-10 for In-Transit Melanoma in Journal of Surgical Oncology, Shows Disease Control Achieved In 63% Of Patients On 11.7 Month Follow Up
Benzinga
Thursday, May 19, 2016
Provectus Biopharma Reports Abstract Availabl...
Benzinga
Friday, April 22, 2016
Provectus Will Report Data on PV-10 in Combo Therapy, T-Cell Mediated Immunity at AACR Meeting
Benzinga
UPDATE: Provectus Says Presentation Showed Tr...
Benzinga
Provectus Biopharmaceuticals Reports Data On PV-10 in Combination Therapy and T Cell Mediated Immunity Presented at AACR Annual Meeting 2016
Benzinga
Wednesday, March 30, 2016
Provectus Biopharma Reports Q4 Cash, Cash Equ...
Benzinga
Wednesday, March 16, 2016
Provectus Biopharmaceuticals Amends Protocol for Phase 3 Study of PV-10 in Treatment of Locally Advanced Cutaneous Melanoma
Benzinga
Provectus Biopharmaceuticals Files Non-Timely...
Benzinga
Provectus Announces Results of Internal Investigation of Audit Committee
Benzinga
Monday, February 29, 2016
Provectus Biopharmaceuticals Says Initiates P...
Benzinga
Wednesday, January 20, 2016
Top Performing Industries For January 20, 2016
Benzinga
Tuesday, January 12, 2016
Provectus Biopharma Announces First Patents f...
Benzinga
Tuesday, September 29, 2015
Provectus Biopharmaceuticals Reports Publication of Review Paper on PV-10 Tumor Ablation and Immune Stimulation
Benzinga
Tuesday, August 18, 2015
Provectus Biopharmaceuticals Given US Patent Protecting Use of PV-10 as Part of Combination Therapy for Cancer
Benzinga
Wednesday, July 22, 2015
Provectus Biopharmaceuticals to Hold Q2 Business Update Conference Call on Thursday, August 6, 2015
Benzinga
Monday, July 06, 2015
Provectus Biopharmaceuticals' Phase 1 PV-10 Data on Liver Cancer Presented at 6th Asia-Pacific Primary Liver Cancer Expert Meeting
Benzinga
Thursday, July 02, 2015
Provectus Biopharma Reports Signing of Letter...
Benzinga
Wednesday, June 24, 2015
Provectus Biopharmaceuticals Announces Abstract Available on PV-10 for Chemoablation of Liver Cancers at ESMO 17th World Congress on Gastrointestinal Cancer
Benzinga
Friday, June 19, 2015
Provectus Biopharma Prices Offering of 17.5M ...
Benzinga
Thursday, June 18, 2015
Provectus Biopharma Announces Intention Of Pu...
Benzinga
Monday, June 01, 2015
Provectus Biopharmaceuticals' Data on PV-10 as Intralesional Treatment of Melanoma Presented at 2015 American Society of Clinical Oncology Annual Meeting
Benzinga
Monday, May 18, 2015
Provectus Biopharmaceuticals Extends for 60 D...
Benzinga
Monday, April 20, 2015
Pfizer and Provectus Biopharmaceuticals Receive Patent Allowance for Use of PV-10 in Combination with Systemic Immunotherapy Agents in Treatment of Cancer
Benzinga
Wednesday, April 15, 2015
Provectus Biopharmaceuticals Opens Patient Enrollment; Starts Phase 3 International FDA Comparative Clinical Trial of PV-10 for Melanoma
Benzinga
Thursday, March 12, 2015
Provectus Biopharmaceuticals Awarded PH-10 Patent by USPTO
Benzinga
Tuesday, January 27, 2015
Stocks With Unusual Volume For Jan 27: HQY, P...
Benzinga
Tuesday, December 23, 2014
Provectus Biopharmaceuticals' Protocol for Ph...
Benzinga
Monday, December 22, 2014
Provectus Biopharmaceuticals to Meet with FDA on Operational Aspects of PV-10 Phase 3 Melanoma Study with Aim to Maximize Speed
Benzinga
Thursday, November 06, 2014
Provectus Biopharmaceuticals Submits PV-10 Ph...
Benzinga
Provectus Shares Halted News Pending
Benzinga
Tuesday, October 14, 2014
INC Research Signs Agreement to Perform FDA D...
Benzinga
Monday, September 29, 2014
Provectus Biopharmaceuticals Presents Data Showing Ablative, Bystander Effects of PV-10 at ESMO 2014
Benzinga
Monday, August 18, 2014
Provectus Biopharmaceuticals Enters into Non...
Benzinga
Tuesday, July 08, 2014
Provectus Biopharma Says it's In Position to Embark on Phase 3 Study of Intralesional PV-10 for Metastatic Melanoma
Benzinga
Tuesday, June 24, 2014
Provectus Biopharmaceuticals Shares Spike Lower; May be Attributed to Seeking Alpha Post
Benzinga
Thursday, June 12, 2014
Mid-Day Market Movers For Thursday, June 12, 2014
Benzinga
Provectus Biopharmaceuticals to Discuss Outline of Phase 3 Clinical Trial Of PV-10 To Treat Melanoma
Benzinga
Show More
